10.6084/m9.figshare.11888520.v1
Sinead Toomey
Sinead
Toomey
Aoife Carr
Aoife
Carr
Mateusz Mezynski
Mateusz
Mezynski
Yasir Elamin
Yasir
Elamin
Shereen Rafee
Shereen
Rafee
Mattia Cremona
Mattia
Cremona
Clare Morgan
Clare
Morgan
Stephen Madden
Stephen
Madden
Khairun Abdul-Jalil
Khairun
Abdul-Jalil
Kathy Gately
Kathy
Gately
Angela Farrelly
Angela
Farrelly
Elaine Kay
Elaine
Kay
Susan Kennedy
Susan
Kennedy
Kenneth O’Byrne
Kenneth
O’Byrne
Liam Grogan
Liam
Grogan
Oscar Breathnach
Oscar
Breathnach
Patrick Morris
Patrick
Morris
Alexander Eustace
Alexander
Eustace
Joanna Fay
Joanna
Fay
Robert Cummins
Robert
Cummins
Anthony O’Grady
Anthony
O’Grady
Roshni Kalachand
Roshni
Kalachand
Norma O’Donovan
Norma
O’Donovan
Fergal Kelleher
Fergal
Kelleher
Aine O’Reilly
Aine
O’Reilly
Mark Doherty
Mark
Doherty
John Crown
John
Crown
Bryan Hennessy
Bryan
Hennessy
Additional file 1 of Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples
Springer Nature
2020
tumor samples
metastatic tumour samples
Colorectal B
Table S 1. List
Table S 2. Somatic mutations
KRAS mutations
PIK 3CA
oncogenic mutations
Breast tumour cohorts
tumour types
Table S 8. Frequency
RPPA
tumour samples
Phase Protein Array
Table S 6. Somatic mutation status
catalog number
Agena MassArray technology
host species
Table S 4. Antibodies
Table S 7. Somatic mutation status
2020-02-23 04:40:00
Journal contribution
https://springernature.figshare.com/articles/journal_contribution/Additional_file_1_of_Identification_and_clinical_impact_of_potentially_actionable_somatic_oncogenic_mutations_in_solid_tumor_samples/11888520
Additional file 1: Figure S1. Breakdown of tumour types in A. Colorectal B. Lung and C. Breast tumour cohorts. Table S1. List of mutations analysed using the Agena MassArray technology. Table S2. Somatic mutations tested subdivided by pathway. Table S4. Antibodies used for Reverse Phase Protein Array (RPPA), including the company from which it was purchased, the catalog number, the host species and the dilution at which it was used. Table S6. Somatic mutation status in samples taken from two different regions of the same primary tumour. Samples identified in one sample but not in the other are identified in bold print. Table S7. Somatic mutation status of primary and matched metastatic tumour samples. Samples identified in one sample but not in the other are identified in bold print. Table S8. Frequency and co-occurrence of somatic PIK3CA and KRAS mutations in solid tumour samples.